The new funding will support Trailhead’s efforts to commercialize iPSC-derived human cells for research and drug discovery applications.
FDA feedback suggests rexlemestrocel-L may reduce chronic back pain and opioid use, Phase 3 underway.
South China Morning Post says it spoke with the iPSC research team, who relayed that the brain stem cell implant is showing promise in Parkinson’s.
AlloJoin is the first KOA stem cell therapy to reach Phase III in China, and it’s gearing up for production soon.
The latest funding round will support US expansion, new stem cell-derived disease models, and increased manufacturing at its Edinburgh site.
The companies aim to streamline workflows by integrating AI-driven automation, data connectivity, and advanced scientific instruments.
The acquisition brings expanded expertise in regenerative medicine, tissue repair, and biomaterials to Dark Horse Consulting’s service portfolio.
Building on its momentum in the East, MEDIPOST received a Phase 2 waver, and is heading right for Phase 3 in the US this year. This is one to watch.
The partnership will focus on bringing oral mucosal stem cell therapy for diabetic foot ulcers to Florida, with FDA trials planned.
FDA clearance of Theracor introduces a new sheet-form umbilical cord device, expanding options for advanced wound care management.
The new graft material is designed for improved integration with patients’ tissues, and it’s available through distributors now.
Japan’s SAKIGAKE designation may help accelerate development and review of the embryonic stem cell-derived therapy.
The new funding will support Trailhead’s efforts to commercialize iPSC-derived human cells for research and drug discovery applications.
FDA feedback suggests rexlemestrocel-L may reduce chronic back pain and opioid use, Phase 3 underway.
South China Morning Post says it spoke with the iPSC research team, who relayed that the brain stem cell implant is showing promise in Parkinson’s.
AlloJoin is the first KOA stem cell therapy to reach Phase III in China, and it’s gearing up for production soon.
The latest funding round will support US expansion, new stem cell-derived disease models, and increased manufacturing at its Edinburgh site.
The companies aim to streamline workflows by integrating AI-driven automation, data connectivity, and advanced scientific instruments.
The acquisition brings expanded expertise in regenerative medicine, tissue repair, and biomaterials to Dark Horse Consulting’s service portfolio.
Building on its momentum in the East, MEDIPOST received a Phase 2 waver, and is heading right for Phase 3 in the US this year. This is one to watch.
The partnership will focus on bringing oral mucosal stem cell therapy for diabetic foot ulcers to Florida, with FDA trials planned.
FDA clearance of Theracor introduces a new sheet-form umbilical cord device, expanding options for advanced wound care management.
The new graft material is designed for improved integration with patients’ tissues, and it’s available through distributors now.
Japan’s SAKIGAKE designation may help accelerate development and review of the embryonic stem cell-derived therapy.
